ADNI- Alzheimer's Disease Neuroimaging Initiative is a continuing,multicenter, longitudinal study that aims to create biomarkers for Alzheimer's disease that canbe used for early monitoring and detection (AD). Alzheimer's-Disease affects thinking and memory while also causing the overall size of the mind to decrease, ultimately leading to death. The development of more effective treatments for AD depends on an early diagnosis of the condition. A subset of artificial intelligence known as machine learning (ML), uses a number of probabilistic and optimization techniques to help computers learn from huge and complicated datasets. In order to diagnose AD in its early stages, researchers typically use machine learning.The work that has recently been done towards the early identification of AD using ML approaches is reviewed, analysed, and critically evaluated in this publication. Although several approaches showed potential prediction accuracies, it was challenging to compare them fairly because their evaluations were based on diverse pathologically untested data sets from various imaging modalities. The evaluation of prediction accuracy is also significantly influenced by a number of additional variables, including preprocessing, the quantity of crucial attributes for Feature’s selection, and Class-Imbalance.The most effective classifiers currently integrate the best features from a variety of imaging techniques, including fluorodeoxy glucose-PET, MRI, clinical testing and CSF biomarkers. We discuss the various detection techniques in this article.

neurodegeneration; Alzheimer’s disease; protein; disease-modifying therapy;risk factors; chaperons;